Skip to content
The Policy VaultThe Policy Vault

Nerlynx (neratinib) — United Healthcare

Node-positive breast cancer

Initial criteria

  • Diagnosis of early-stage breast cancer AND Disease is HER2-positive AND Used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy (e.g., Herceptin, Kanjinti)
  • OR Diagnosis of node positive breast cancer AND Disease is HR-positive and HER2-positive AND Used as extended adjuvant therapy following adjuvant trastuzumab-containing therapy (e.g., Herceptin, Kanjinti) AND Patient has a perceived high risk of recurrence

Approval duration

12 months per occurrence